Washington Growth Strategies LLC Takes $397,000 Position in MiniMed Group Inc $MMED

Washington Growth Strategies LLC acquired a new stake in shares of MiniMed Group Inc (NASDAQ:MMED – Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 26,587 shares of the company’s stock, valued at approximately $397,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Legal & General Group Plc bought a new position in MiniMed Group in the 2nd quarter valued at $91,000. The Manufacturers Life Insurance Company bought a new position in shares of MiniMed Group in the second quarter worth $185,000. Punch & Associates Investment Management Inc. bought a new position in shares of MiniMed Group in the second quarter worth $292,000. Deutsche Bank AG purchased a new stake in shares of MiniMed Group in the second quarter worth $420,000. Finally, Bank of New York Mellon Corp bought a new stake in MiniMed Group during the second quarter valued at $1,058,000.

Get MiniMed Group alerts:

MiniMed Group News Roundup

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Analysts see further upside: Citigroup and Wells Fargo issued forecasts calling for strong price appreciation, while analysts at Mizuho, UBS Group, Bank of America and BTIG Research also said MiniMed’s share price is expected to rise. The cluster of bullish views may support investor confidence and buying interest. Citigroup forecast Wells Fargo forecast Mizuho analyst view UBS analyst view Bank of America analyst view BTIG analyst view
• Positive Sentiment: New products are driving optimism: A recent product introduction helped lift MiniMed’s top line, with further launches scheduled over the coming months. Investors appear to be viewing the product pipeline as a potential source of sustained growth. Why MiniMed stock was soaring
• Positive Sentiment: Operational momentum is improving: Coverage highlights recurring revenue streams, regulatory progress and a strong beginning to fiscal 2027, reinforcing the case for more predictable growth. Recurring revenues and product cycle Fiscal 2027 progress
• Neutral Sentiment: Morgan Stanley raised its target: The firm increased its target from $19 to $21 and maintained an “overweight” rating. However, the new target remains below the referenced recent trading level, suggesting that some expected gains may already be reflected in the valuation.

Analyst Upgrades and Downgrades

MMED has been the topic of a number of research analyst reports. Citigroup upped their target price on MiniMed Group from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday. BTIG Research lifted their price target on MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Wells Fargo & Company boosted their price objective on MiniMed Group from $22.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday. Bank of America upped their price objective on shares of MiniMed Group from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings upgraded shares of MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.77.

Get Our Latest Research Report on MiniMed Group

MiniMed Group Price Performance

Shares of NASDAQ:MMED opened at $23.28 on Friday. The stock has a market capitalization of $6.55 billion and a price-to-earnings ratio of -34.24. MiniMed Group Inc has a 52-week low of $10.65 and a 52-week high of $24.43. The stock has a fifty day moving average of $18.21.

MiniMed Group (NASDAQ:MMED – Get Free Report) last released its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. The business’s revenue was up 15.6% on a year-over-year basis. Equities analysts predict that MiniMed Group Inc will post 0.7 earnings per share for the current fiscal year.

About MiniMed Group

(Free Report)

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

Featured Articles

• Five stocks we like better than MiniMed Group
• Revolution Medicines Got Its Breakthrough—What Moves It Next?
• Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
• FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
• AST SpaceMobile Stock Soared 12%—This Was the Catalyst

Want to see what other hedge funds are holding MMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiniMed Group Inc (NASDAQ:MMED – Free Report).

Receive News & Ratings for MiniMed Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiniMed Group and related companies with MarketBeat.com's FREE daily email newsletter.